Latest Headlines

Latest Headlines

UPDATED: Sanofi-backed MyoKardia nabs a $46M round for cardio pipeline construction

Sanofi partner MyoKardia is getting a fresh injection of capital, garnering $46 million in its Series B as the South San Francisco-based biotech plots the next stage of its clinical journey developing new drugs for genetically defined groups of heart patients.

Q3 biotech venture investing makes a boisterous leap

The life sciences industry gained a blast of good news on the venture front today. The National Venture Capital Association and PricewaterhouseCoopers outlined a buoyant set of numbers for the...

Third Rock bankrolls a new biotech to tackle genetic heart disease

Third Rock Ventures has dipped back into its second fund for a $38 million A round to launch a new drug developer which plans to get into the genetic nitty-gritty of heart disease.